Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 lutikizumab study in adults with moderate to severe hidradenitis suppurativa after anti-TNF failure
2020-004108-33Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lutikizumab in hidradenitis suppurativa (HS) (4 arms), sponsored by AbbVie Inc. Primary endpoint: HiSCR at Week 16. Started Dec 2021; status: completed.
02
Drugs
lutikizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2020-004108-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004108-33.